Cargando…

Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer

To examine whether the predictive performance of prostate-specific antigen (PSA) and PSA-related markers for prostate cancer (PCa) is modified by body mass index (BMI). Patients with a PSA 2–10 ng/mL who underwent multicore prostate biopsies were recruited from three tertiary centers. Serum markers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yao, Han, Cheng-Tao, Zhang, Gui-Ming, Liu, Fang, Ding, Qiang, Xu, Jian-Feng, Vidal, Adriana C., Freedland, Stephen J., Ng, Chi-Fai, Ye, Ding-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709513/ https://www.ncbi.nlm.nih.gov/pubmed/26754552 http://dx.doi.org/10.1038/srep19034

Ejemplares similares

Development and external validation of a prostate health index-based nomogram for predicting prostate cancer
por: Zhu, Yao, et al.
Publicado: (2015)

Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort
por: Tang, Bo, et al.
Publicado: (2017)

Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer
por: Huang, Da, et al.
Publicado: (2021)

PSA mass as a marker of prostate cancer progression after radical prostatectomy
por: Bryniarski, Piotr, et al.
Publicado: (2011)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Beyond PSA: The Role of Prostate Health Index (phi)
por: Ferro, Matteo, et al.
Publicado: (2020)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China
por: Zhang, Gui-Ming, et al.
Publicado: (2015)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Aspirin and prostate cancer prevention
por: Vidal, Adriana C., et al.
Publicado: (2015)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis
por: Wang, Wenying, et al.
Publicado: (2014)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

Management of a localized prostatic adenocarcinoma despite the very high rate of PSA and the large tumor mass: Does PSA level indicate the stage of prostate cancer?
por: el Farhaoui, Hammou, et al.
Publicado: (2023)

Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China
por: Xu, Libo, et al.
Publicado: (2017)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population
por: Wu, Yi-Shuo, et al.
Publicado: (2018)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Re: Commentary on “The association between sexual function and prostate cancer risk in US veterans”
por: Vidal, Adriana C, et al.
Publicado: (2018)

Higher Body Mass Index Increases the Risk for Biopsy-Mediated Detection of Prostate Cancer in Chinese Men
por: Hu, Meng-Bo, et al.
Publicado: (2015)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2016)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study
por: Park, Hongzoo, et al.
Publicado: (2018)

PSA mass screening: is there enough evidence?
por: Rocco, Bernardo, et al.
Publicado: (2012)

The Prognostic Role of Body Mass Index on Oncological Outcomes of Upper Tract Urothelial Carcinoma
por: Liu, Kang, et al.
Publicado: (2023)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
por: Yoneyama, Tohru, et al.
Publicado: (2021)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients
por: Klaassen, Zachary, et al.
Publicado: (2014)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer
por: Fryczkowski, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6v1f793sh1eeu1r7mp56jnif10